Scientifically-based approaches to evaluate medications that limit brain exposure to methamphetamine, modulate methamphetamine effects at vesicular monoamine transporter-2, or target dopaminergic, serotonergic, gamma-aminobutyric acid (GABA)-ergic, and/or glutamatergic brain pathways have already been underway [19,59] and despite the increasing efforts made to review medications for the treatment of methamphetamine dependence, many of these trials failed to consider their course of action on cue-induced reactivity. This evidence concerns the gene SLC18A2 and methamphetamine dependence.